Matches in Nanopublications for { ?s ?p ?o <http://rdf.disgenet.org/nanopublications.trig#NP100313.RAeJ-rEWwv_Up8FaPtKl6YXMlR51-tdSv_Zgx4QTUJ9fU130_provenance>. }
Showing items 1 to 9 of
9
with 100 items per page.
- source_evidence_literature type ECO_0000212 NP100313.RAeJ-rEWwv_Up8FaPtKl6YXMlR51-tdSv_Zgx4QTUJ9fU130_provenance.
- source_evidence_literature label "DisGeNET evidence - LITERATURE" NP100313.RAeJ-rEWwv_Up8FaPtKl6YXMlR51-tdSv_Zgx4QTUJ9fU130_provenance.
- source_evidence_literature comment "Gene-disease associations inferred from text-mining the literature." NP100313.RAeJ-rEWwv_Up8FaPtKl6YXMlR51-tdSv_Zgx4QTUJ9fU130_provenance.
- NP100313.RAeJ-rEWwv_Up8FaPtKl6YXMlR51-tdSv_Zgx4QTUJ9fU130_assertion description "[Examine therapeutic targeting of the endothelin-A receptor in human ovarian carcinoma/that efficacy of cytotoxic agents is markedly enhanced by co-administration with atrasentan.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP100313.RAeJ-rEWwv_Up8FaPtKl6YXMlR51-tdSv_Zgx4QTUJ9fU130_provenance.
- NP100313.RAeJ-rEWwv_Up8FaPtKl6YXMlR51-tdSv_Zgx4QTUJ9fU130_assertion evidence source_evidence_literature NP100313.RAeJ-rEWwv_Up8FaPtKl6YXMlR51-tdSv_Zgx4QTUJ9fU130_provenance.
- NP100313.RAeJ-rEWwv_Up8FaPtKl6YXMlR51-tdSv_Zgx4QTUJ9fU130_assertion SIO_000772 15838262 NP100313.RAeJ-rEWwv_Up8FaPtKl6YXMlR51-tdSv_Zgx4QTUJ9fU130_provenance.
- NP100313.RAeJ-rEWwv_Up8FaPtKl6YXMlR51-tdSv_Zgx4QTUJ9fU130_assertion wasDerivedFrom lhgdn-20090331 NP100313.RAeJ-rEWwv_Up8FaPtKl6YXMlR51-tdSv_Zgx4QTUJ9fU130_provenance.
- NP100313.RAeJ-rEWwv_Up8FaPtKl6YXMlR51-tdSv_Zgx4QTUJ9fU130_assertion wasGeneratedBy ECO_0000203 NP100313.RAeJ-rEWwv_Up8FaPtKl6YXMlR51-tdSv_Zgx4QTUJ9fU130_provenance.
- lhgdn-20090331 importedOn "2009-03-31" NP100313.RAeJ-rEWwv_Up8FaPtKl6YXMlR51-tdSv_Zgx4QTUJ9fU130_provenance.